Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Perceptive Advisors LLC

Perceptive Advisors LLC increased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 2.1% during the fourth quarter, Holdings Channel reports. The firm owned 25,132,364 shares of the biopharmaceutical company’s stock after acquiring an additional 522,664 shares during the quarter. Amicus Therapeutics makes up 4.8% of Perceptive Advisors LLC’s portfolio, making the stock its 6th biggest holding. Perceptive Advisors LLC owned approximately 0.10% of Amicus Therapeutics worth $244,789,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nisa Investment Advisors LLC lifted its holdings in Amicus Therapeutics by 145.9% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,270 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 1,940 shares in the last quarter. Quantbot Technologies LP increased its stake in Amicus Therapeutics by 82.1% in the 4th quarter. Quantbot Technologies LP now owns 9,699 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 4,373 shares during the last quarter. Sage Capital Advisors llc bought a new stake in Amicus Therapeutics in the 4th quarter worth approximately $99,000. Neo Ivy Capital Management bought a new stake in Amicus Therapeutics in the 4th quarter worth approximately $111,000. Finally, Tower Research Capital LLC TRC increased its stake in Amicus Therapeutics by 12,246.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 12,346 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 12,246 shares during the last quarter.

A number of analysts have issued reports on FOLD shares. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. ValuEngine raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, March 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Amicus Therapeutics in a research note on Tuesday, February 4th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, January 9th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $18.09.

NASDAQ:FOLD traded down $0.45 during trading hours on Thursday, reaching $9.44. The stock had a trading volume of 3,383,810 shares, compared to its average volume of 3,574,431. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.93 and a current ratio of 4.04. Amicus Therapeutics, Inc. has a 52 week low of $6.25 and a 52 week high of $14.61. The company has a 50 day moving average price of $9.62 and a two-hundred day moving average price of $9.35. The stock has a market capitalization of $2.42 billion, a PE ratio of -6.25 and a beta of 1.26.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, March 2nd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.09). The company had revenue of $55.29 million for the quarter, compared to the consensus estimate of $54.01 million. Amicus Therapeutics had a negative net margin of 195.56% and a negative return on equity of 60.83%. Equities research analysts predict that Amicus Therapeutics, Inc. will post -0.99 EPS for the current year.

In other news, insider Ellen Rosenberg sold 22,100 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $10.35, for a total transaction of $228,735.00. Following the transaction, the insider now owns 185,350 shares of the company’s stock, valued at approximately $1,918,372.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Bradley L. Campbell sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $10.01, for a total value of $25,025.00. Following the transaction, the chief operating officer now directly owns 347,695 shares in the company, valued at approximately $3,480,426.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 262,892 shares of company stock worth $2,598,084. Corporate insiders own 2.50% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Story: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.